{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:24:14Z","timestamp":1788456254942,"version":"build-2803163510"},"reference-count":145,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T00:00:00Z","timestamp":1591056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Mucosal healing (MH) is the key therapeutic target of inflammatory bowel disease (IBD). The evaluation of MH remains challenging, with endoscopy being the golden standard. We performed a comprehensive overview of the performance of fecal-, serum-, and urine-based biochemical markers in colonic IBD to find out whether we are ready to replace endoscopy with a non-invasive but equally accurate instrument. A Pubmed, Web of Knowledge, and Scopus search of original articles as potential MH markers in adults, published between January 2009 and March 2020, was conducted. Finally, 84 eligible studies were identified. The most frequently studied fecal marker was calprotectin (44 studies), with areas under the curves (AUCs) ranging from 0.70 to 0.99 in ulcerative colitis (UC) and from 0.70 to 0.94 in Crohn`s disease (CD), followed by lactoferrin (4 studies), matrix metalloproteinase-9 (3 studies), and lipocalin-2 (3 studies). The most frequently studied serum marker was C-reactive protein (30 studies), with AUCs ranging from 0.60 to 0.96 in UC and from 0.64 to 0.93 in CD. Fecal calprotectin is an accurate MH marker in IBD in adults; however, it cannot replace endoscopy and the application of calprotectin is hampered by the lack of standardization concerning the cut-off value. Other markers are either not sufficiently accurate or have not been studied extensively enough.<\/jats:p>","DOI":"10.3390\/diagnostics10060367","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T04:12:09Z","timestamp":1591157529000},"page":"367","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Biochemical Biomarkers of Mucosal Healing for Inflammatory Bowel Disease in Adults"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2753-8092","authenticated-orcid":false,"given":"Ma\u0142gorzata","family":"Krzystek-Korpacka","sequence":"first","affiliation":[{"name":"Department of Medical Biochemistry, Wroclaw Medical University, Chalubinskiego 10, 50-368 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rados\u0142aw","family":"Kempi\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0806-6608","authenticated-orcid":false,"given":"Mariusz","family":"Bromke","sequence":"additional","affiliation":[{"name":"Department of Medical Biochemistry, Wroclaw Medical University, Chalubinskiego 10, 50-368 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3650-9311","authenticated-orcid":false,"given":"Katarzyna","family":"Neubauer","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,6,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1053\/j.gastro.2016.12.004","article-title":"Inflammatory bowel disease 2017: Innovations and changing paradigms","volume":"152","author":"Colombel","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/ibd\/izx111","article-title":"Network medicine: A mandatory next step for inflammatory bowel disease","volume":"4","author":"deSouza","year":"2018","journal-title":"Inflam. Bowel Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.crohns.2013.09.016","article-title":"European evidence based consensus for endoscopy in inflammatory bowel disease","volume":"7","author":"Annese","year":"2013","journal-title":"J. Crohn's Colitis"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1053\/j.gastro.2007.05.051","article-title":"Mucosal healing in inflammatory bowel disease: Results from a Norwegian population-based cohort","volume":"133","author":"Jahnsen","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.cgh.2010.12.028","article-title":"Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis","volume":"9","author":"Ardizzone","year":"2011","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1053\/j.gastro.2011.06.054","article-title":"Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis","volume":"141","author":"Colombel","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1053\/j.gastro.2003.11.010","article-title":"Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis","volume":"126","author":"Rutter","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1136\/gut.2003.038505","article-title":"Cancer surveillance in longstanding ulcerative colitis: Endoscopic appearances help predict cancer risk","volume":"53","author":"Rutter","year":"2004","journal-title":"Gut"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting therapeutic targets in inflammatory bowel disease (STRIDE): Determining therapeutic goals for treat-to-target","volume":"110","author":"Sandborn","year":"2015","journal-title":"Am. J. Gastroenterol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/apt.13475","article-title":"Systematic review with meta-analysis: Mucosal healing is associated with improved long-term outcomes in Crohn\u2019s disease","volume":"43","author":"Shah","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1097\/MIB.0000000000000816","article-title":"Endoscopic mucosal healing predicts favorable clinical outcomes in inflammatory bowel disease: A meta-analysis","volume":"22","author":"Reinink","year":"2016","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn\u2019s disease: The ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn\u2019s disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S434","DOI":"10.14309\/00000434-201010001-01190","article-title":"Achievement of early deep remission predicts better long-term outcomes for adalimumab-treated patients with Crohn\u2019s disease: Data from EXTEND","volume":"105","author":"Sanborn","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1136\/gutjnl-2012-302830","article-title":"Mucosal healing in inflammatory bowel diseases: A systemic review","volume":"61","author":"Neurath","year":"2012","journal-title":"Gut"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study","volume":"317","author":"Schroeder","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","article-title":"ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: Initial diagnosis, monitoring of known IBD, detection of complications","volume":"13","author":"Maaser","year":"2019","journal-title":"J. Crohn's Colitis"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/ecco-jcc\/jjy114","article-title":"ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects","volume":"13","author":"Sturm","year":"2019","journal-title":"J. Crohn's Colitis"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00535-018-1439-1","article-title":"Evidence-based clinical practice guidelines for inflammatory bowel disease","volume":"53","author":"Matsuoka","year":"2018","journal-title":"J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1053\/j.gastro.2013.07.024","article-title":"Reliability and initial validation of the Ulcerative Colitis Endoscopic Index of Severity","volume":"145","author":"Travis","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cgh.2012.08.003","article-title":"Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures","volume":"11","author":"Samuel","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1136\/gut.30.7.983","article-title":"Development and validation of an endoscopic index of the severity for Crohn\u2019s disease: A prospective multicentre study","volume":"30","author":"Mary","year":"1989","journal-title":"Gut"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0016-5107(04)01878-4","article-title":"Development and validation of a new, simplified endoscopic activity score for Crohn\u2019s disease: The SES-CD","volume":"60","author":"Daperno","year":"2004","journal-title":"Gastrointest. Endosc."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1002\/ibd.21300","article-title":"Endoscopic evaluation of Crohn\u2019s disease activity: Comparison of the CDEIS and the SES-CD","volume":"16","author":"Sipponen","year":"2010","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"528","DOI":"10.3109\/00365521.2012.660542","article-title":"Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn\u2019s disease","volume":"47","author":"Nieminen","year":"2012","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/bs.acc.2018.07.005","article-title":"Fecal calprotectin","volume":"87","author":"Ayling","year":"2018","journal-title":"Adv. Clin. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1002\/ibd.22917","article-title":"Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease","volume":"18","author":"Ferrante","year":"2012","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.3109\/00365521.2011.584897","article-title":"Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers","volume":"46","author":"Ricanek","year":"2011","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/ajg.2009.545","article-title":"Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn\u2019s Disease (SES-CD) than CRP, blood leukocytes, and the CDAI","volume":"105","author":"Schoepfer","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1002\/ibd.20986","article-title":"Ulcerative colitis: Correlation of the Rachmilewitz Endoscopic Activity Index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes","volume":"15","author":"Schoepfer","year":"2009","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.dld.2017.12.022","article-title":"Accuracy of fecal calprotectin for the prediction of endoscopic activity in patients with inflammatory bowel disease","volume":"50","author":"Chaparro","year":"2018","journal-title":"Dig. Liv. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"325","DOI":"10.3109\/00365520903483650","article-title":"Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn\u2019s disease treatment","volume":"45","author":"Sipponen","year":"2010","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/00365521.2018.1549683","article-title":"Low fecal calprotectin predicts clinical remission in Crohn\u2019s disease patients: The simple answer to a challenging question","volume":"54","author":"Monteiro","year":"2019","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Shimoyama, T., Yamamoto, T., Umegae, S., and Shimoyama, M. (2018). Faecal calprotectin level for assessing endoscopic activity and predicting future clinical course in patients with moderately active ulcerative colitis undergoing granulomonocytapheresis: A prospective cohort study. BMC Gastroenterol., 18.","DOI":"10.1186\/s12876-018-0853-4"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.crohns.2011.11.002","article-title":"Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF na\u00efve patients with ulcerative colitis","volume":"6","author":"Dewit","year":"2012","journal-title":"J. Crohn's Colitis"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"546","DOI":"10.5217\/ir.2018.00052","article-title":"Experience of patients with inflammatory bowel disease in using a home fecal calprotectin test as an objective reported outcome for self-monitoring","volume":"16","author":"Wei","year":"2018","journal-title":"Intest. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/MIB.0000000000000619","article-title":"Fecal calprotectin measured by patients at home using smartphones\u2014a new clinical tool in monitoring patients with inflammatory bowel disease","volume":"22","author":"Vinding","year":"2016","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"353","DOI":"10.5114\/aoms.2014.43672","article-title":"Is faecal calprotectin equally useful in all Crohn\u2019s disease locations? A prospective, comparative study","volume":"11","author":"Eder","year":"2015","journal-title":"Arch. Med. Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3109\/00365521.2015.1008035","article-title":"Impact of disease location on fecal calprotectin levels in Crohn\u2019s disease","volume":"50","author":"Gecse","year":"2015","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1093\/ecco-jcc\/jjv150","article-title":"Endoscopic factors influencing fecal calprotectin value in Crohn\u2019s disease","volume":"9","author":"Goutorbe","year":"2015","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1080\/00365521.2018.1482956","article-title":"The sensitivity of fecal calprotectin in predicting deep remission in ulcerative colitis","volume":"53","author":"Carlsen","year":"2018","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/jgh3.12074","article-title":"Optimal cut-off value of fecal calprotectin for the evaluation of ulcerative colitis: An unsolved issue?","volume":"2","author":"Jha","year":"2018","journal-title":"JGH Open"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1007\/s10620-018-4980-0","article-title":"Fecal calprotectin in assessing endoscopic and histological remission in patients with ulcerative colitis","volume":"63","author":"Mak","year":"2018","journal-title":"Dig. Dis. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1159\/000484223","article-title":"Correlation of fecal markers with magnifying endoscopic stratification in patients with ulcerative colitis who are in clinical remission","volume":"97","author":"Mine","year":"2018","journal-title":"Digestion"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/ecco-jcc\/jjy184","article-title":"Defining faecal calprotectin thresholds as a surrogate for endoscopic and histological disease activity in ulcerative colitis\u2013a prospective analysis","volume":"13","author":"Walsh","year":"2018","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"8235","DOI":"10.3748\/wjg.v23.i46.8235","article-title":"Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China","volume":"23","author":"Chen","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"7387","DOI":"10.3748\/wjg.v23.i41.7387","article-title":"Fecal calprotectin measurement is a marker of short term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease","volume":"23","author":"Kostas","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Lee, S.H., Kim, M.J., Chang, K., Song, E.M., Hwang, S.W., Park, S.H., Yang, D.H., Kim, K.J., Byeon, J.S., and Myung, S.J. (2017). Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis. BMC Gastroenterol., 17.","DOI":"10.1186\/s12876-017-0669-7"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1097\/MIB.0000000000001157","article-title":"Fecal Calprotectin Levels Predict Histological Healing in Ulcerative Colitis","volume":"23","author":"Patel","year":"2017","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Hiraoka, S., Takashima, S., Inokuchi, T., Nakarai, A., Takahara, M., Harada, K., Seki, Y., Watanabe, K., Kato, J., and Okada, H. The novel latex agglutination turbidimetric immunoassay system for simultaneous measurements of calprotectin and hemoglobin in feces. Intest. Res., 2018.","DOI":"10.5217\/ir.2018.00086"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/MIB.0000000000000652","article-title":"Low fecal calprotectin correlates with histological remission and mucosal healing in ulcerative colitis and colonic Crohn\u2019s disease","volume":"22","author":"Zittan","year":"2016","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1093\/ecco-jcc\/jjw044","article-title":"Faecal lactoferrin, calprotectin, PMN-elastase, CRP, and white blood cell count as indicators for mucosal healing and clinical course of disease in patients with mild to moderate ulcerative colitis: Post hoc analysis of a prospective clinical trial","volume":"10","author":"Langhorst","year":"2016","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"13566","DOI":"10.3748\/wjg.v21.i48.13566","article-title":"Taiwan Society of Inflammatory Bowel Disease Multicenter Study. Fecal calprotectin correlated with endoscopic remission for Asian inflammatory bowel disease patients","volume":"21","author":"Lin","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1097\/MIB.0b013e3182802b6e","article-title":"A new rapid quantitative test for fecal calprotectin predicts endoscopic activity in ulcerative colitis","volume":"19","author":"Lopez","year":"2013","journal-title":"Inflam. Bowel Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1097\/MIB.0b013e3182807577","article-title":"Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases","volume":"19","author":"Nancey","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"509","DOI":"10.4318\/tjg.2012.0421","article-title":"The value of fecal calprotectin as a marker of intestinal inflammation in patients with ulcerative colitis","volume":"23","author":"Beyazit","year":"2012","journal-title":"Turk. J. Gastroenterol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/MIB.0b013e3182810066","article-title":"Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes","volume":"19","author":"Schoepfer","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1097\/MIB.0000000000000341","article-title":"Disease activity assessment in IBD: Clinical indices and biomarkers fail to predict endoscopic remission","volume":"21","author":"Falvey","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/ecco-jcc\/jju015","article-title":"Prediction of endoscopic disease activity in ulcerative colitis by two different assays for fecal calprotectin","volume":"9","author":"Kristensen","year":"2015","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1097\/MEG.0000000000000461","article-title":"Clinical application of faecal calprotectin in ulcerative colitis patients","volume":"27","author":"Scaioli","year":"2015","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/ajg.2015.66","article-title":"Evaluation of mucosal healing in ulcerative colitis by fecal calprotectin vs. fecal immunochemical test","volume":"110","author":"Takashima","year":"2015","journal-title":"Am. J. Gastroenterol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/j.cgh.2015.05.038","article-title":"Level of fecal calprotectin correlates with endoscopic and histologic inflammation and identifies patients with mucosal healing of ulcerative colitis","volume":"13","author":"Theede","year":"2015","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"273","DOI":"10.15403\/jgld.2014.1121.233.thv","article-title":"Rapid fecal calprotectin level assessment and the SIBDQ score can accurately detect active mucosal inflammation in IBD patients in clinical remission: A prospective study","volume":"23","author":"Voiosu","year":"2014","journal-title":"J. Gastrointest. Liver Dis."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/jgh.13061","article-title":"Fecal calprotectin is a clinically relevant biomarker of mucosal healing in patients with quiescent ulcerative colitis","volume":"31","author":"Yamaguchi","year":"2016","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"169","DOI":"10.15403\/jgld-177","article-title":"Serum trefoil factor 3 predicts disease activity in patients with ulcerative colitis","volume":"28","author":"Nakov","year":"2019","journal-title":"J. Gastrointest. Liver Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1093\/ecco-jcc\/jjz107","article-title":"Faecal calprotectin predicts endoscopic and histological activity in clinically quiescent ulcerative colitis","volume":"14","author":"Hart","year":"2020","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1080\/00365513.2019.1622148","article-title":"Improved monitoring of inflammatory activity in patients with ulcerative colitis by combination of faecal tests for haemoglobin and calprotectin","volume":"79","author":"Karling","year":"2019","journal-title":"Scand. J. Clin. Lab. Investig."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3904\/kjim.2016.324","article-title":"The usefulness of fecal calprotectin in assessing inflammatory bowel disease activity","volume":"34","author":"Lee","year":"2019","journal-title":"Korean J. Intern. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e17080","DOI":"10.1097\/MD.0000000000017080","article-title":"Clinical implications of fecal calprotectin and fecal immunochemical test on mucosal status in patients with ulcerative colitis","volume":"98","author":"Ryu","year":"2019","journal-title":"Medicine"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1111\/jgh.14310","article-title":"Prediction of disease activity of Crohn\u2019s disease through fecal calprotectin evaluated by balloon-assisted endoscopy","volume":"33","author":"Iwamoto","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1756284818769075","article-title":"Monitoring Crohn\u2019s disease activity: Endoscopy, fecal markers and computed tomography enterography","volume":"11","author":"Lopes","year":"2018","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_73","first-page":"130","article-title":"Accurate cut-offs for predicting endoscopic activity and mucosal healing in Crohn\u2019s disease with fecal calprotectin","volume":"109","author":"Machancoses","year":"2016","journal-title":"Rev. Esp. Enferm. Dig."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cgh.2016.08.015","article-title":"Level of fecal calprotectin correlates with severity of small bowel Crohn\u2019s disease, measured by balloon-assisted enteroscopy and computed tomography enterography","volume":"15","author":"Arai","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1097\/MIB.0000000000000728","article-title":"Fecal immunochemical test versus fecal calprotectin for prediction of mucosal healing in Crohn\u2019s disease","volume":"22","author":"Inokuchi","year":"2016","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e641","DOI":"10.1016\/j.crohns.2013.05.005","article-title":"A new rapid test for fecal calprotectin predicts endoscopic remission and postoperative recurrence in Crohn\u2019s disease","volume":"7","author":"Ruiz","year":"2013","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.crohns.2014.02.014","article-title":"Serum ficolin-2 correlates worse than fecal calprotectin and CRP with endoscopic Crohn\u2019 disease activity","volume":"8","author":"Schaffer","year":"2014","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3109\/08916934.2015.1016221","article-title":"Selected biologic markers of inflammation and activity of Crohn\u2019s disease","volume":"48","author":"Karczewski","year":"2015","journal-title":"Autoimmunity"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1097\/MIB.0000000000001173","article-title":"Noninvasive fecal immunochemical testing and fecal calprotectin predict mucosal healing in inflammatory bowel disease: A prospective cohort study","volume":"23","author":"Ma","year":"2017","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1097\/MIB.0000000000000736","article-title":"Fecal calprotectin predicts relapse and histological mucosal healing in ulcerative colitis","volume":"22","author":"Theede","year":"2016","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s10620-016-4397-6","article-title":"High Percentage of IBD patients with indefinite fecal calprotectin levels: Additional value of a combination score","volume":"62","author":"Bodelier","year":"2017","journal-title":"Dig. Dis. Sci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1515\/cclm-2018-1063","article-title":"Faecal calprotectin in inflammatory bowel diseases: A review focused on meta-analyses and routine usage limitations","volume":"57","author":"Lucendo","year":"2019","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.dld.2009.07.002","article-title":"Diagnostic value of faecal calprotectin in unselected outpatients referred for colonoscopy: A multicenter prospective study","volume":"42","author":"Meucci","year":"2010","journal-title":"Dig. Liver Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1097\/MIB.0000000000001136","article-title":"Fecal calprotectin is not affected by pregnancy: Clinical implications for the management of pregnant patients with inflammatory bowel disease","volume":"23","author":"Julsgaard","year":"2017","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1080\/00365521.2019.1566493","article-title":"Proton pump inhibitor use is associated with elevated faecal calprotectin levels. A cross-sectional study on subjects referred for colonoscopy","volume":"4","author":"Lundgren","year":"2019","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_86","first-page":"26","article-title":"The intra-individual variability of faecal calprotectin: A prospective study in patients with active ulcerative colitis","volume":"9","author":"Lasson","year":"2015","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Toyonaga, T., Kobayashi, T., Nakano, M., Saito, E., Umeda, S., Okabayashi, S., Ozaki, R., and Hibi, T. (2017). Usefulness of fecal calprotectin for the early prediction of short-term outcomes of remission induction treatments in ulcerative colitis in comparison with two-item patient-reported outcome. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0185131"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"396","DOI":"10.14740\/jocmr3275e","article-title":"Fecal Calprotectin: A comparison of two commercial enzymoimmunoassays and study of fecal extract stability at room temperature","volume":"10","author":"Acevedoa","year":"2018","journal-title":"J. Clin. Med. Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1080\/00365521.2016.1256424","article-title":"Clinical implications of assay-specific differences in f-calprotectin when monitoring inflammatory bowel disease activity over time","volume":"52","author":"Amcoff","year":"2016","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_90","first-page":"312","article-title":"Rapid fecal calprotectin test for prediction of mucosal inflammation in ulcerative colitis and Crohn disease: A prospective cohort study","volume":"127","author":"Moniuszko","year":"2017","journal-title":"Pol. Arch. Intern. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/ibd.22996","article-title":"Fecal MMP-9: A new noninvasive differential diagnostic and activity marker in ulcerative colitis","volume":"19","author":"Farkas","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1097\/MCG.0000000000000837","article-title":"Fecal matrix metalloprotease-9 and lipocalin-2 as biomarkers in detecting endoscopic activity in patients with inflammatory bowel diseases","volume":"52","author":"Buisson","year":"2018","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/ecco-jcc\/jjv005","article-title":"The diagnostic value of a new fecal marker, matrix metalloprotease-9, in different types of inflammatory bowel diseases","volume":"9","author":"Farkas","year":"2015","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/codi.13258","article-title":"Faecal lactoferrin is a useful biomarker for mucosal healing in patients with ulcerative colitis during granulocyte and monocyte adsorptive apheresis therapy","volume":"18","author":"Sagawa","year":"2016","journal-title":"Colorectal Dis."},{"key":"ref_95","first-page":"435","article-title":"Portuguese IBD Study Group [GEDII. Accuracy of faecal calprotectin and neutrophil gelatinase B-associated lipocalin in evaluating subclinical inflammation in UlceRaTIVE colitis-the ACERTIVE study","volume":"11","author":"Magro","year":"2017","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/jgh.13598","article-title":"Fecal neutrophil gelatinase-associated lipocalin as a biomarker for inflammatory bowel disease","volume":"32","author":"Thorsvik","year":"2017","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1159\/000446210","article-title":"Fecal human neutrophil peptide levels correlate with intestinal inflammation in ulcerative colitis","volume":"93","author":"Kanmura","year":"2016","journal-title":"Digestion"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ejim.2015.06.015","article-title":"The diagnostic usefulness of fecal lactoferrin in the assessment of Crohn\u2019s disease activity","volume":"26","author":"Klimczak","year":"2015","journal-title":"Eur. J. Intern. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.crohns.2011.07.010","article-title":"Serum adenosine deaminase activity as a predictor of disease severity in ulcerative colitis","volume":"6","author":"Beyazit","year":"2012","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1097\/MIB.0000000000000068","article-title":"Neutrophil gelatinase B-associated lipocalin and matrix metalloproteinase-9 complex as a surrogate serum marker of mucosal healing in ulcerative colitis","volume":"20","author":"Arijs","year":"2014","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"149","DOI":"10.5152\/tjg.2016.15408","article-title":"A rapid test for assessing disease activity in ulcerative colitis","volume":"27","author":"Dranga","year":"2016","journal-title":"Turk. J. Gastroenterol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"238","DOI":"10.4103\/sjg.SJG_599_16","article-title":"Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis","volume":"23","author":"Hassan","year":"2017","journal-title":"Saud. J. Gastroenterol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.dld.2012.05.011","article-title":"Correlation between soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) expression and endoscopic activity in inflammatory bowel diseases","volume":"44","author":"Jung","year":"2012","journal-title":"Dig. Liver Dis."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"7265812","DOI":"10.1155\/2018\/7265812","article-title":"Diagnostic potential of systemic eosinophil-associated cytokines and growth factors in IBD","volume":"2018","author":"Neubauer","year":"2018","journal-title":"Gastroenterol. Res. Pract."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/MIB.0b013e3182802b0e","article-title":"Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission","volume":"19","author":"Rosenberg","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s12664-015-0608-x","article-title":"Fecal calprotectin and its correlation with inflammatory markers and endoscopy in patients from India with inflammatory bowel disease","volume":"34","author":"Samant","year":"2015","journal-title":"Indian J. Gastroenterol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/ecco-jcc\/jjw132","article-title":"Leucine-rich Alpha-2 glycoprotein is a serum biomarker of mucosal healing in ulcerative colitis","volume":"11","author":"Shinzaki","year":"2017","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Tran, D.H., Wang, J., Ha, C., Ho, W., Mattai, S.A., Oikonomopoulos, A., Weiss, G., Lacey, P., Cheng, M., and Shieh, C. (2017). Circulating cathelicidin levels correlate with mucosal disease activity in ulcerative colitis, risk of intestinal stricture in Crohn\u2019s disease, and clinical prognosis in inflammatory bowel disease. BMC Gastroenterol., 17.","DOI":"10.1186\/s12876-017-0619-4"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jgh3.12017","article-title":"Blood biomarkers reflect integration of severity and extent of endoscopic inflammation in ulcerative colitis","volume":"1","author":"Uchihara","year":"2017","journal-title":"JGH Open"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s10620-013-2907-3","article-title":"Correlations of C-reactive protein levels and erythrocyte sedimentation rates with endoscopic activity indices in patients with ulcerative colitis","volume":"59","author":"Yoon","year":"2014","journal-title":"Dig. Dis. Sci."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/ecco-jcc\/jjv148","article-title":"Serum neutrophil gelatinase B-associated lipocalin and matrix metalloproteinase-9 complex as a surrogate marker for mucosal healing in patients with Crohn\u2019s disease","volume":"9","author":"Arijs","year":"2015","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/ecco-jcc\/jjx124","article-title":"Sepsis Markers Soluble IL-2 Receptor and soluble CD14 subtype as potential biomarkers for complete mucosal healing in patients with inflammatory bowel disease","volume":"12","author":"Hosomi","year":"2018","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.dld.2017.12.010","article-title":"Serum amyloid A level correlated with endoscopic findings in patients with Crohn\u2019s disease-Possible biomarker for evaluating mucosal healing","volume":"50","author":"Ishihara","year":"2018","journal-title":"Dig. Liver Dis."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.gastrohep.2016.01.015","article-title":"Correlation between serological biomarkers and endoscopic activity in patients with inflammatory bowel disease","volume":"39","author":"Chaparro","year":"2016","journal-title":"Gastroenterol. Hepatol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/MIB.0000000000000991","article-title":"Serum Amyloid A as a surrogate marker for mucosal and histologic inflammation in patients with Crohn\u2019s disease","volume":"23","author":"Yarur","year":"2017","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1684\/ecn.2015.0363","article-title":"Usefulness of selected laboratory markers in ulcerative colitis","volume":"26","author":"Adamski","year":"2015","journal-title":"Eur. Cytokine Netw."},{"key":"ref_117","first-page":"178","article-title":"Diagnostic accuracy of fecal calprotectin in assessing the severity of inflammatory bowel disease: From laboratory to clinic","volume":"8","author":"Moein","year":"2017","journal-title":"Casp. J. Intern. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e678","DOI":"10.1016\/j.crohns.2013.06.008","article-title":"Serum calprotectin as a biomarker for Crohn\u2019s disease","volume":"7","author":"Meuwis","year":"2013","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.3748\/wjg.v23.i22.4039","article-title":"Systemic interleukin-9 in inflammatory bowel disease: Association with mucosal healing in ulcerative colitis","volume":"23","author":"Matusiewicz","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1007\/s10620-018-5446-0","article-title":"Serum procalcitonin as a potential early predictor of short-term outcomes in acute severe ulcerative colitis","volume":"64","author":"Wu","year":"2019","journal-title":"Dig. Dis. Sci."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"8335","DOI":"10.3748\/wjg.v19.i45.8335","article-title":"Clinical significance of serum procalcitonin in patients with ulcerative colitis","volume":"19","author":"Koido","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/j.1365-2036.2010.04459.x","article-title":"Additional benefit of procalcitonin to C-reactive protein to assess disease activity and severity in Crohn\u2019s disease","volume":"32","author":"Oussalah","year":"2010","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_123","first-page":"CR563","article-title":"Elevated markers of thrombin generation and fibrinolysis in patients with active and quiescent ulcerative colitis","volume":"15","author":"Zezos","year":"2009","journal-title":"Med. Sci. Monit."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3748\/wjg.v23.i1.135","article-title":"Trefoil factor-3 is not a useful marker of mucosal healing in Crohn\u2019s disease treated with anti-TNF-\u03b1 antibodies","volume":"23","author":"Eder","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"9541370","DOI":"10.1155\/2017\/9541370","article-title":"Reduced transferrin levels in active inflammatory bowel disease","volume":"2017","author":"Matusiewicz","year":"2017","journal-title":"Biomed. Res. Int."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"e569","DOI":"10.1016\/j.crohns.2013.04.005","article-title":"Relationship between levels of angiogenic and lymphangiogenic factors and the endoscopic, histological and clinical activity, and acute-phase reactants in patients with inflammatory bowel disease","volume":"7","author":"Algaba","year":"2013","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1136\/jim-2016-000062","article-title":"Serum ST2 in inflammatory bowel disease: A potential biomarker for disease activity","volume":"64","author":"Boga","year":"2016","journal-title":"J. Investig. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.3748\/wjg.v17.i17.2181","article-title":"Soluble ST2: A new and promising activity marker in ulcerative colitis","volume":"17","author":"Candia","year":"2011","journal-title":"World J. Gastroenterol."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"D\u00edaz-Jim\u00e9nez, D., De la Fuente, M., Dubois-Camacho, K., Landskron, G., Fuentes, J., P\u00e9rez, T., Gonz\u00e1lez, M.J., Simian, D., Hermoso, M.A., and Quera, R. (2016). Soluble ST2 is a sensitive clinical marker of ulcerative colitis evolution. BMC Gastroenterol., 16.","DOI":"10.1186\/s12876-016-0520-6"},{"key":"ref_130","first-page":"859","article-title":"Serum neutrophil gelatinase-associated lipocalin (NGAL) correlates with clinical and endoscopic activity in ulcerative colitis but fails to predict activity in Crohn\u2019s disease","volume":"68","author":"Budzynska","year":"2017","journal-title":"J. Physiol. Pharmacol."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Neubauer, K., Bednarz-Misa, I., Walecka-Zacharska, E., Wierzbicki, J., Agrawal, A., Gamian, A., and Krzystek-Korpacka, M. (2019). Oversecretion and overexpression of nicotinamide phosphoribosyltransferase\/Pre-B Colony-Enhancing Factor\/Visfatin in inflammatory bowel disease reflects the disease activity, severity of inflammatory response and hypoxia. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20010166"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1002\/ibd.22865","article-title":"Role of serum cytokine profile in ulcerative colitis assessment","volume":"18","author":"Muntane","year":"2012","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/ecco-jcc\/jjv075","article-title":"Serum human trefoil factor 3 is a biomarker for mucosal healing in ulcerative colitis patients with minimal disease activity","volume":"9","author":"Srivastava","year":"2015","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_134","first-page":"3336","article-title":"Positive association between leptin serum levels and disease activity on endoscopy in inflammatory bowel disease: A case-control study","volume":"15","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"ofv098","DOI":"10.1093\/ofid\/ofv098","article-title":"Acute Phase Reactants in Infections: Evidence-based review and a guide for clinicians","volume":"2","author":"Markanday","year":"2015","journal-title":"Open Forum Infect. Dis."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"353","DOI":"10.4292\/wjgpt.v7.i3.353","article-title":"Overview of cytokines and nitric oxide involvement in immuno-pathogenesis of inflammatory bowel diseases","volume":"7","author":"Soufli","year":"2016","journal-title":"World J. Gastrointest. Pharmacol. Ther."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1007\/s10620-009-1016-9","article-title":"Circulating cytokines reflect mucosal inflammatory status in patients with Crohn\u2019s disease","volume":"55","author":"Ljuca","year":"2010","journal-title":"Dig. Dis. Sci."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1097\/MIB.0000000000001172","article-title":"Serum interleukin 9 levels predict disease severity and the clinical efficacy of infliximab in patients with Crohn\u2019s disease","volume":"23","author":"Feng","year":"2017","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1007\/s10620-017-4717-5","article-title":"Ratio of circulating estrogen receptors beta and alpha (ER\u03b2\/ER\u03b1) indicates endoscopic activity in patients with Crohn\u2019s disease","volume":"62","author":"Linares","year":"2017","journal-title":"Dig. Dis. Sci."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/MCG.0000000000001002","article-title":"Inflammatory cytokine profile in Crohn\u2019s disease nonresponders to optimal antitumor necrosis factor therapy","volume":"53","author":"Yarur","year":"2019","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_141","first-page":"788","article-title":"Serum trefoil factor 3 predicts disease activity in patients with ulcerative colitis","volume":"23","author":"Nakov","year":"2019","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1097\/MIB.0000000000000062","article-title":"Prostaglandin E-major urinary metabolite as a reliable surrogate marker for mucosal inflammation in ulcerative colitis","volume":"20","author":"Arai","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: A systematic review of population-based studies","volume":"390","author":"Ng","year":"2018","journal-title":"Lancet"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1038\/ajg.2016.441","article-title":"Biomarkers in Search of Precision Medicine in IBD","volume":"111","author":"Boyapati","year":"2016","journal-title":"Am. J. Gastroenterol."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Torres, J., Petralia, F., Sato, T., Wang, P., Telesco, S.E., Choung, R.S., Strauss, R., Li, X.-J., Laird, R.M., and Gutierrez, R.L. (2020). Serum biomarkers identify patients who will develop inflammatory bowel diseases up to 5 y before diagnosis. Gastroenterology.","DOI":"10.1053\/j.gastro.2020.03.007"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/10\/6\/367\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:35:09Z","timestamp":1760175309000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/10\/6\/367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,2]]},"references-count":145,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["diagnostics10060367"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics10060367","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,2]]}}}